Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer

Clinical Lung Cancer

Volumn 6, Issue SUPPL. 1, 2004, Pages S7-

  Herbst, Roy S ^a   Sandler, Alan B ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cetuximab; Erlotinib; Gefitinib; HER1 EGFR; Monoclonal antibody; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BLP 25; BORTEZOMIB; CANCER VACCINE; CANERTINIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; ISIS 3521; LAPATINIB; MATUZUMAB; NAVELBINE; PACLITAXEL; PANITUMUMAB; PELITINIB; PEMETREXED; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER SURVIVAL; CELLULITIS; CHILL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONSTIPATION; COUGHING; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; DRUG POTENTIATION; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; DYSPEPSIA; ESOPHAGITIS; FATIGUE; FEVER; HEMATURIA; HUMAN; INFECTION; LEUKOPENIA; LICENSING; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MUTATIONAL ANALYSIS; NAUSEA AND VOMITING; NONHUMAN; PATIENT SELECTION; PNEUMONIA; PREDICTION; PROTEIN DOMAIN; REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

EID: 12744271878     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/clc.2004.s.009     Document Type: Review

References (113)

1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002; 97:72-81.
2. Jernal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
3. Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:3390-3399.
4. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130.
5. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16:2459-2465.
6. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-2362.
7. Shepherd FA, Fossella FV, Lynch T, et al. Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol 2001; 28:4-9.
8. Fossella FV. Pemetrexed for treatment of advanced non-small cell lung cancer. Semin Oncol 2004; 31:100-105.
9. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597.
10. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Lite-breaking abstract from the 2004 ASCO Annual Meeting. J Clin Oncol 2004; 22(suppl):7022.
11. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
12. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31:637-643.
13. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(suppl 4):3-8.
14. Veale D, Kerr N, Gibson GJ, et al. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993; 68:162-165.
15. Selvaggi G, Novella S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15:28-32.
16. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7:603-607.
17. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37:9-15.
18. Pfeiffer P, Clausen PP, Andersen K, et al. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996; 74:86-91.
19. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20:975-981.
20. Kanematsu T, Yano S, Uehara H, et al. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 2003; 13:289-298.
21. Pedersen MW, Meltorn M, Damstrup L, et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer thempy. Ann Oncol 2001; 12:745-760.
22. Nagane M, Coufal F, Lin H, et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 1996; 56:5079-5086.
23. Voldborg BR, Damstrup L, Spang-Thomsen M, et al. Epidermal growth factor receptor (EGER) EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997; 8:1197-1206.
24. Garcia de Palazzo IE, Adams GP, Sundareshan P, et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 1993; 53:3217-3220.
25. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55:5536-5539.
26. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
27. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
28. Janne PA. EGFR mutations predict sensitivity to gefitinib - now what? [Education Program] Presented at the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, LA.
29. Pao W, Zakowski M, Cordon-Cardo C, et al. Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib. Proc Am Soc Clin Oncol 2004; 22:619 (Abstract #7025).
30. Kris MG, Sandler A, Miller V, et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). Proc Am Soc Clin Oncol 2004; 23:628 (Abstract #7062).
31. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in non-human cancers to therapeutic target in human neoplasia. J Clin Oncol 2001; 19(suppl 18):32-40.
32. Ranson M, Sliwkowski MX. Perspectives on anti-HER monoclonal antibodies. Oncology 2002; 63(suppl 1): 17-24.
33. Sunada H, Magun BE, Mendelsohn J, et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 1986; 83:3825-3829.
34. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57:4838-4848.
35. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151:1523-1530.
36. Hirata A, Ogawa S, Kometami T, et al. ZD 1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62:2554-2560.
37. Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291:739-748.
38. Higgins B, Kolinsky K, Smith M, et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small-cell lung cancer tumor xenograft models. Anticancer Drugs 2004; 5:503-512.
39. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-4892.
40. Bianco C, Tortora G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8:3250-3258.
41. Karp DD, Silberman S, Csudae R, et al. Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358, 774 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999; 18:388a (Abstract #1499).
42. Hidalgo M, Sïu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267-3279.
43. Ranson M, Hammond LA, Ferry D, et al. ZD 1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20:2240-2250.
44. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20:3815-3825.
45. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
46. Nakagawa K, Tamura T, Negrito S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003; 14:922-930.
47. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904-914.
48. Ranson M, Herbst RS, Fukuoka M, et al. Skin toxicity is not a clinically meaningful prognostic marker for tumour response to gefitinib ('Iressa' ZD1839) in pretreated patients with advanced non-small-cell lung cancer. Presented at: 2nd International Symposium on Signal Transduction Modulators in Cancer Therapy; October 23-25, 2003; Amsterdam, The Netherlands. Abstract C.02.
49. Kelly HC, Ferry D, Hammond L, et al ZD1839 ("Iressa") an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI): pharmacokinetics in a phase 1 study of patients with advanced cancer. Proc Am Assoc Cancer Res 2000; 41:612-613 (Abstract #3896).
50. Perez-Soler R, Chachoua A, Hammond L, et al. Determinants of tumor response and survival with erlotinib in patients with NSCLC. J Clin Oncol 2004; 22:3238-3247.
51. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
52. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
53. Niho S, Kubota K, Goto K, et al. First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II study. Proc Am Soc Clin Oncol 2004; 23:628 (Abstract #7098).
54. Clark G, Perez-Soler R, Siu L, et al. Rash severity is predictive of increased survival with erlotinib HCI. Proc Am Soc Clin Oncol 2003; 22:196 (Abstract #786).
55. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22:204 (Abstract #817).
56. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 2003; 22:252 (Abstract #1012).
57. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-1987.
58. Janne PA, Gurubhagavatula S, Lucca J, et al. Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib ("Iressa," ZD1839) in the compassionate use program. Lung Cancer 2003; 41:571 (Abstract #O-243).
59. Park J, Park BB, Lee SH, et al. Gefitinib ("Iressa," ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41 (suppl):S249 (Abstract #P-620).
60. West H, Franklin WA, Gumerlock PH, et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proc Am Soc Clin Oncol 2004; 23:618 (Abstract #7014).
61. Mohamed MK, Ramalingam S, Lin Y, et al. Skin rash and good performance status (PS) predict improved survival with gefitinib for patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:637 (Abstract #7097).
62. Ervin TJ, Toothaker SR. Community practice experience with gefitinib (ZD1839) as treatment for patients with advanced non-small-cell lung cancer (NSCLC) within an expanded access clinical program. Proc Am Soc Clin Oncol 2004; 23:704 (Abstract #7367).
63. Rowinsky E, Schwartz G, Dutcher J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody: phase II clinical trials in renal cell cancer (RCC). Eur J Cancer 2002; 38:57 (Abstract #178).
64. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10:1212-1218.
65. Lynch TH, Lilenbaum R, Bonomi P, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:634 (Abstract #7084).
66. Mita A, Farouzesh B, Hidalgo M. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor receptor-tyrosine kinase (HER1/EGFR-TK) inhibitor erlotinib (OSI-774; Tarceva) in combination with docetaxel. Eur J Cancer 2002; 38(suppl 7):53 (Abstract #168).
67. Ochs J, Grous JJ, Warner KL. Final survival and safety results for 21,064 non-small-cell lung cancer (NSCLC) patients who received compassionate use gefitinib in a U.S. expanded access program (EAP). Proc Am Soc Clin Oncol 2004; 23:628 (Abstract #7060).
68. Mita M, Patnaik A, Hammond LA, et al. Phase I, pharmacokinetic (PK) and biologic study of erlotinib, (OSI-774) in combination with paclitaxel and carboplatin in advanced solid malignancies. Proc Am Soc Clin Oncol 2003; 22:209 (Abstract #837).
69. George C, Desai A, Janisch L, et al. Phase I trial of erlotinib HCI (E, OSI-774) in combination with gemcitabine (G) and cisplatin (C). Proc Am Soc Clin Oncol 2003; 22:229 (Abstract #916).
70. Jones R, Hanauske AR, Diaz-Rubio E, et al. Final evaluation of Tarceva (erlotinib) in combination with FOLFOX4 in patients with solid tumors. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Nov 17-21, 2003; Boston, MA. Abstract #A108.
71. Trigo J, Baselga J, De Rosa F, et al. A phase IB study of Tarceva™ (erlotinib) plus capecitabine and docetaxel in metastatic breast cancer (updated data) Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; November 17-21, 2003; Boston, MA. Abstract #A74.
72. Van Cutsem E, Beale P, Delord JP, et al. Tarceva™ (erlotinib) in combination with Xeloda™ (capecitabine) and oxaliplatin in patients with metastatic colorectal cancer: a phase I dose escalation trial. Clin Cancer Res 2003; 9(suppl):6095s (Abstract #A109).
73. Fandi A, Gatzemeier U, Smith R, et al. Final data from a pilot trial of gefitinib (ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): safety and pharmacokinetics. Proc Am Soc Clin Oncol 2003; 22:655 (Abstract #2635).
74. Gonzalez-Larriba JL, Giaccone G, van Oosterom AT, et al. ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemonaive patients with advanced solid tumours: final results of a phase I trial. Proc Am Soc Clin Oncol 2002; 21:95a (Abstract #376).
75. Miller VA, Johnson DH, Krug LM, et al. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 2003; 21:2094-2100.
76. Robert F, Blumenschein G, Dicke K, et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22:643 (Abstract #2587).
77. Kollmannsberger C, Schittenhelm M, Honecker F, et al. Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): a phase-I study. Proc Am Soc Clin Oncol 2003; 22:627 (Abstract #2520).
78. Crawford J, Sandler AB, Hammond LA, et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:634 (Abstract #7083).
79. Roche Genentech Pharmaceuticals. Phase III trials of Tarceva plus chemotherapy in lung cancer do not meet primary endpoint. Located at: www.roche.com/med-corp-detail-2003?id=1050&media-language=e. Accessed December 15, 2003.
80. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-794.
81. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784.
82. Herbst RS, Prager D, Hermann R, et al. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:617 (Abstract #7011).
83. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004 23:617 (Abstract #7010).
84. Miller VA, Herbst R, Prager D, et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: sub-group analysis of TRIBUTE. Proc Am Soc Clin Oncol 2004; 23:628 (Abstract #7061).
85. Perez-Soler R, Ling YH, Lia M, et al. Molecular mechanisms of resistance to the HER1/EGFR tyrosine kinase inhibitor erlotinib HCI in human cell lines. Proc Am Soc Clin Oncol 2003; 22:190 (Abstract #762).
86. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark? Lancet 2003; 362:62-64.
87. Gumerlock P, Pryde B, Kimura T, et al. Enhanced cytotoxicicy of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 2003; 22:662 (Abstract #2661).
88. Solit DB, She Y, Moasser MM. Pulsatile administration of the EGF receptor inhibitor Iressa (ZD1839) is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Proc Am Assoc Cancer Res 2003; 44:1318 (Abstract #LB-5).
89. Kimura T, Mahaffey CM, Pryde BJ, et al. Apoptotic effects of the docetaxel-OSI-774 combination in non-small cell lung carcinoma (NSCLC) cells. Proc Am Soc Clin Oncol 2004; 23:649 (Abstract #7143).
90. Kim E, Mauer AM, Tran H, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory resistant patients with advanced non-small-cell lung cancer: Final report. Proc Am Soc Clin Oncol 2003; 22:642 (Abstract #2581).
91. Kelly K, Hanna N, Rosenberg A, et al. A multi-centered phase I/II study of cetuximab in combination with pacitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:644 (Abstract #2592).
92. Rosell R, Daniel C, Ramlau R, et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pcs) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23:618 (Abstract #7012).
93. Williams KJ, Telfer BA, Stratford IJ, et al. ZD1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86:1157-1161.
94. Raben D, Helfrich B, Chan D, et al. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo. Proc Am Soc Clin Oncol 2001; 20:257a (Abstract #1026).
95. Chinnaiyan P, Huang SM, Armstrong E, et al. Modulation of radiation response after HER1/EGFR inhibition by erlotinib (Tarceva) in lung and head and neck carcinoma. Lung Cancer 2003; 41:572 (Abstract #O-246).
96. Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 2000; 48:1519-1528.
97. Mauer AM, Haraf D, Hoffman PC, et al. A phase I study of OSI-774 in combination with chemoradiation (CRT) for unresectable, locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22:651 (Abstract #2617).
98. Rischin D, Burmeister B, Mitchell P, et al. Phase I trial of gefitinib (ZD1839) in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 2004; 23:632 (Abstract #7077).
99. Herbst R, Mininberg ED, Henderson T, et al. Phase I/II trial evaluating blockade of turnout blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer. Eur J Cancer 2003; 1(suppl):S293 (Abstract #977).
100. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleoide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-3747.
101. Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002; 38:1133-1140.
102. Guy SP, Ashton SE, Hughes G, et al. Gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular-targeting agent ZD6126 in human colorectal cancer and non-small cell lung cancer (NSCLC) xenograft models. Clin Cancer Res 2003; 9:6142S (Abstract #B13).
103. Sandler AB, Blumenschein GR, Henderson T, et al. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Proc Am Soc Clin Oncol 2004; 23:127 (Abstract #2000).
104. Azzariti A, Xu JM, Porcelli L, et al. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa trade mark, ZD1839). Biochem Pharmacol 2004; 68:135-144.
105. Bianco R, Bianco C, Caputo R et al. Selective inhibition of the epidermal growth factor receptor tyrosine kinase (HER1/EGFR-TK) by ZD1839 ('Iressa') potentiates the antitumor effects of ionizing radiation. Proc Am Assoc Cancer Res 2002; 43:1003 (Abstract #A4972).
106. Perez-Soler K HER1/EGFR targeting: refining the strategy. Oncologist 2004; 58-67.
107. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:1103-1109.
108. Read WL, Page NC, Tierney RM, et al. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer 2004; 45:137-142.
109. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002; 74:1640-1646.
110. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21:3798-3807.
111. Franklin WA, Gumerlock PH, Crowley J, et al. EGFR, HER2 and ERB-B pathway activation in bronchioaloalveolar carcinoma (BAC): analysis of SWOG 9417 and lung SPORE tissue samples. Proc Am Soc Clin Oncol 2003; 22:620 (Abstract #2493).
112. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22:133-142.
113. Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal anti-body in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22:3003-3015.